BeyondSpring (NASDAQ:BYSI) Shares Up 1.3% – Should You Buy?

Posted by Tammy Falkenburg on Jul 29th, 2026

Shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) rose 1.3% on Tuesday . The company traded as high as $1.1850 and last traded at $1.1850. 6,587 shares changed hands during trading, a decline of 78% from the average session volume of 29,945 shares. The stock had previously closed at $1.17.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Check Out Our Latest Research Report on BeyondSpring

BeyondSpring Stock Up 1.3%

The stock has a market cap of $48.73 million, a P/E ratio of -8.46 and a beta of 0.43. The stock has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $1.56.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC raised its position in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 16.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the period. Geode Capital Management LLC owned approximately 0.91% of BeyondSpring worth $601,000 as of its most recent filing with the SEC. Institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.